Allarity Therapeutics settles $4.9 million Novartis liability for $1.0 million payment
Allarity Therapeutics entered a Settlement and Release Agreement with Novartis Pharma AG on October 28, 2026, resolving a liability of $4.9 million plus interest tied to a license agreement that was terminated effective January 26, 2024. Novartis agreed to accept $1.0 million as full payment, and both parties will release claims once the payment is received. Separately, the company announced on October 30, 2026 its first revenue-generating contract under its CLIA-certified laboratory services strategy, but the filing does not disclose the contract's value.
Key points
- Liability owed to Novartis: $4.9 million plus interest, arising under a license agreement between Novartis and Allarity Therapeutics Europe ApS, an affiliate
- Settlement payment: $1.0 million, accepted by Novartis as full payment of the liability upon receipt
- Mutual releases of claims take effect upon receipt of the payment, subject to claims relating to enforcement of the agreement
- October 30, 2026 press release: first revenue-generating contract under the CLIA-certified laboratory services strategy; contract value not disclosed
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.